<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073892</url>
  </required_header>
  <id_info>
    <org_study_id>PROGEN-PR88201</org_study_id>
    <secondary_id>CDR0000335412</secondary_id>
    <secondary_id>COMIRB-01-207</secondary_id>
    <nct_id>NCT00073892</nct_id>
  </id_info>
  <brief_title>PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma</brief_title>
  <official_title>A Phase I/II Study Of PI-88 In Advanced Malignancies (Phase I), And In Advanced Melanoma(Phase II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Progen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medigen Biotechnology Corporation</source>
  <brief_summary>
    <textblock>
      RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have&#xD;
      an advanced malignancy (cancer) or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Phase I&#xD;
&#xD;
        -  Determine the maximum tolerated dose of PI-88 in patients with an advanced malignancy.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
      Phase II&#xD;
&#xD;
        -  Determine the progression-free survival and time to progression in patients with stage&#xD;
           IV melanoma treated with this drug.&#xD;
&#xD;
        -  Determine the biological activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
        -  Phase I (parts 1 and 2):&#xD;
&#xD;
             -  Part 1: Patients receive PI-88 subcutaneously (SC) once daily on days 1-4 and&#xD;
                15-18.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of PI-88 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD has been determined in part I, the&#xD;
      effect of dose frequency is determined in patients in part II.&#xD;
&#xD;
        -  Part 2: Patients receive PI-88 SC once daily on days 1-4, 8-11, 15-18, and 22-25 at a&#xD;
           dose based on the MTD determined in part 1.&#xD;
&#xD;
      Cohorts of 3 patients receive escalating doses of PI-88 until the MTD at this frequency is&#xD;
      determined.&#xD;
&#xD;
        -  Phase II (patients with metastatic melanoma): Patients receive PI-88 as in phase I, part&#xD;
           2 at the MTD.&#xD;
&#xD;
      Treatment in both phases repeats every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-69 patients (18-30 for phase I [part 1], 6-9 for phase I&#xD;
      [part 2], and 25-30 for phase II) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Analysis</measure>
    <time_frame>end of Cycle 6 of study treatment (24 weeks)</time_frame>
    <description>non-progression rate (objective response or stable disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Analysis</measure>
    <time_frame>were time to progressive disease, survival, duration of partial response, complete response and stable disease</time_frame>
    <description>time to progression and overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Melanoma (Skin)</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>PI-88</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive four consecutive days treatment each week in a 4-week cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI-88</intervention_name>
    <description>250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle</description>
    <arm_group_label>PI-88</arm_group_label>
    <other_name>Mannopentaose phosphate sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Phase I&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy&#xD;
&#xD;
          -  No other effective treatment available OR failed prior therapy&#xD;
&#xD;
          -  No prior or concurrent symptomatic or known CNS involvement or brain or meningeal&#xD;
             metastases&#xD;
&#xD;
        Phase II&#xD;
&#xD;
          -  Diagnosis of stage IV melanoma&#xD;
&#xD;
          -  Metastatic disease must be measurable&#xD;
&#xD;
          -  No other effective treatment available OR failed prior therapy&#xD;
&#xD;
          -  Asymptomatic brain metastases allowed provided patient is off steroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Negative serotonin release assay test for anti-heparin antibodies&#xD;
&#xD;
          -  No other abnormal bleeding tendency&#xD;
&#xD;
          -  No history of heparin-induced thrombocytopenia&#xD;
&#xD;
          -  No history of immune-mediated thrombocytopenia&#xD;
&#xD;
          -  No history of thrombolytic thrombocytopenic purpura&#xD;
&#xD;
          -  No history of other platelet disease&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  PTT normal (20-34 sec)&#xD;
&#xD;
          -  PT less than 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min OR&#xD;
&#xD;
          -  Glomerular filtration rate greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No stroke within the past 3 months&#xD;
&#xD;
          -  No congestive heart failure within the past 3 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of acute or chronic gastrointestinal bleeding within the past 2 years&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No serious infection within the past 4 weeks&#xD;
&#xD;
          -  No history of alcohol, drug, or other substance abuse&#xD;
&#xD;
          -  No history of allergy and/or hypersensitivity to anti-coagulants/thrombolytic agents&#xD;
             (e.g., heparin)&#xD;
&#xD;
          -  No risk of bleeding due to open wounds or planned surgery&#xD;
&#xD;
          -  No clinically significant nonmalignant disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Current diagnosis of metastatic melanoma, where other effective therapy was not&#xD;
             available or had failed.&#xD;
&#xD;
          -  Measurable disease. Metastatic lesions had to have been measurable by MRI or CT, and&#xD;
             cutaneous lesions by physical examination.&#xD;
&#xD;
          -  Biopsiable Lesion Group only: Must have had at least one biopsiable lesion that was&#xD;
             bi-dimensionally measurable and previously unirradiated.&#xD;
&#xD;
          -  Ageâ‰¥ 18 years.&#xD;
&#xD;
          -  Have voluntarily given written informed consent to participate in this study.&#xD;
&#xD;
          -  Performance status: ECOG 0 - 2 (Karnofsky 70 -100%).&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Neutrophil count &gt; 1.5 x 109/L (1,500/mm3).&#xD;
&#xD;
          -  Platelet count &gt; 100 x 109/L (100,000/mm3).&#xD;
&#xD;
          -  APTT normal (20 - 34 sec).&#xD;
&#xD;
          -  PT &lt;1.5 x ULN.&#xD;
&#xD;
          -  Calculated creatinine clearance, using the Cockcroft-Gault formula, &gt;60 mL/min. If&#xD;
             just below 60 mL/min, then GFR&gt;60 mL/min as determined by EDTA or DTPA scan.&#xD;
&#xD;
          -  Bilirubin &lt;1.5 x ULN.&#xD;
&#xD;
          -  AST and ALT up to 2 x ULN; except in the presence of liver metastases; up to 5 x ULN.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current symptomatic central nervous system involvement, or active brain or meningeal&#xD;
             metastases.&#xD;
&#xD;
          -  Concomitant use of aspirin (&gt; 100 mg/day), non-steroidal anti-inflammatory drugs (with&#xD;
             the exception of COX-2 inhibitors), heparin, low molecular weight heparin or warfarin&#xD;
             (&gt; 1 mg/day) which was ongoing or anticipated during the study period. Low-dose&#xD;
             aspirin (100 mg/day or less) or low-dose warfarin (1 mg/day or less) was permitted.&#xD;
&#xD;
          -  Heparin or low molecular weight heparin within the previous 2 weeks.&#xD;
&#xD;
          -  Chemotherapy, investigational therapy or hormonal therapy in the previous 4 weeks.&#xD;
&#xD;
          -  Radiotherapy to a major bone marrow bearing area such as pelvis, femoral heads,&#xD;
             lumbar-sacral spine, within the previous 4 weeks. Radiotherapy to other sites within&#xD;
             the previous 2 weeks.&#xD;
&#xD;
          -  History of allergy and/or hypersensitivity to anti-coagulants/thrombolytic agents,&#xD;
             especially heparin.&#xD;
&#xD;
          -  History of heparin-induced thrombocytopenia, immune mediated thrombocytopenia,&#xD;
             thrombotic thrombocytopenic purpura and/or other platelet diseases, or laboratory&#xD;
             evidence of anti-heparin antibodies.&#xD;
&#xD;
          -  Myocardial infarction, stroke or congestive heart failure within the previous 3 months&#xD;
&#xD;
          -  History of acute or chronic gastrointestinal bleeding within the previous two years,&#xD;
             inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk&#xD;
             of bleeding due to open wounds or planned surgery.&#xD;
&#xD;
          -  Uncontrolled infection or serious infection within the previous 4 weeks.&#xD;
&#xD;
          -  Clinically significant non-malignant disease.&#xD;
&#xD;
          -  Known AIDS-related illness or HIV positive.&#xD;
&#xD;
          -  Women who were pregnant, breast feeding, or of childbearing potential in whom&#xD;
             pregnancy could not be excluded.&#xD;
&#xD;
          -  History of abuse of alcohol, drugs or other substances.&#xD;
&#xD;
          -  Not recovered from major surgery if conducted prior to the study.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy to a major bone-marrow bearing area (e.g.,&#xD;
             pelvis, femoral heads, or lumbar-sacral spine)&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior heparin or low-molecular weight heparin&#xD;
&#xD;
          -  More than 4 weeks since other prior investigational therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No concurrent aspirin or aspirin-containing medications&#xD;
&#xD;
          -  No concurrent nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
               -  Concurrent cyclooxygenase-2 inhibitors allowed&#xD;
&#xD;
          -  No concurrent heparin or low-molecular weight heparin&#xD;
&#xD;
          -  No concurrent warfarin or warfarin-containing medications&#xD;
&#xD;
          -  No other concurrent anticoagulant medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. G. Eckhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital - Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

